Potential remains for PPAR-targeted drugs.
Jones
Dan
D
D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology*; D047492:Peroxisome Proliferator-Activated Receptors / Q000187:drug effects* / Q000378:metabolism
D007004:Hypoglycemic Agents; D047492:Peroxisome Proliferator-Activated Receptors
Lancet. 2009 Jul 11;374(9684):126-35
19515415
Nature. 2010 Jul 22;466(7305):451-6
20651683